News Warner Logo

News Warner

Simple tool can help uncover underdiagnosed back condition

Simple tool can help uncover underdiagnosed back condition

  • A new study has developed an innovative online screening questionnaire called the A-tool to help identify people with underdiagnosed back conditions, specifically axial spondyloarthritis (axSpA).
  • The A-tool consists of a brief set of clinical questions that patients can complete themselves without a physician intermediary, and it has shown to increase the probability of detection from 5% to 33%.
  • According to researchers, the simplicity, practicality, and feasibility of the A-tool make it an effective tool for flagging patients for timely referral to a rheumatologist, improving their chances of receiving an accurate diagnosis.
  • The study found that among the 100 participants who were fully evaluated, about one in three were diagnosed with axSpA, highlighting the potential of the A-tool to identify individuals with low back pain due to this condition.
  • The researchers hope to refine the A-tool further and make it accessible to anyone, aiming to empower patients to spot warning signs sooner and bring relief to those living with back pain.

A man grasps at his lower back in pain.

A simple screening tool can help uncover an underdiagnosed back condition, a new study finds.

For millions of people living with back pain, the cause is often elusive. One underrecognized culprit is axial spondyloarthritis (axSpA)—a form of inflammatory arthritis that primarily affects the spine and sacroiliac joints of the hips.

Left undiagnosed, axSpA can lead to chronic back pain, stiffness, reduced mobility, and diminished quality of life. On average, patients may suffer pain for eight to twelve years before receiving the correct diagnosis.

“This type of diagnostic delay is unacceptable in the current day and age,” says Yale School of Medicine’s Abhijeet Danve. “We do have medications to treat this condition effectively, but patients are often diagnosed late—or never diagnosed at all.”

Danve and colleagues are working to change that. Their new study in Rheumatology Advances in Practice tested an innovative online screening questionnaire—known as the A-tool—to help identify people who may have axSpA and guide them to the right care more quickly.

Unlike previously proposed screening methods and referral strategies, which often require specialized imaging or blood tests, the A-tool consists of a brief set of clinical questions. Patients can complete it themselves, without a physician intermediary. Distributed through electronic health record portals and Facebook in the study, the tool quickly reached more than 1,200 patients who reported chronic back pain. Among the 100 participants who were fully evaluated, about one in three were diagnosed with axSpA.

The simplicity, practicality, and feasibility of the A-tool are its strengths, the researchers say. By cutting through the complexity of diagnosing back pain, it improves the odds of flagging patients for timely referral to a rheumatologist.

“Our tool increases the probability of detection from 5% to 33%, which is a huge improvement,” says Danve, an associate professor of medicine (rheumatology, allergy, and immunology).

For patients, the message is clear: persistent back pain—especially in younger adults—shouldn’t be ignored. Early recognition can open the door to effective treatment, including biologic therapies that improve function and quality of life.

“The results of this work can help identify individuals who potentially have low back pain due to axial spondylarthritis, which can be treated with appropriate medications,” says coauthor Insoo Kang, professor of medicine (rheumatology, allergy, and immunology).

Danve hopes to refine the A-tool further by modifying the questionnaire and creating an online calculator that is accessible to anyone. His broader goal is patient empowerment toward early diagnosis and effective treatment.

“Patients are their own best advocates,” Danve says. “By giving them the means to spot warning signs sooner, this research could help shorten the road to diagnosis and bring relief to many living with back pain.”

Source: Yale

The post Simple tool can help uncover underdiagnosed back condition appeared first on Futurity.

link

Q. What is axial spondyloarthritis (axSpA) and how does it affect the body?
A. Axial spondyloarthritis (axSpA) is a form of inflammatory arthritis that primarily affects the spine and sacroiliac joints of the hips, leading to chronic back pain, stiffness, reduced mobility, and diminished quality of life.

Q. Why is axSpA often underdiagnosed?
A. AxSpA is often underdiagnosed because its symptoms can be similar to those of other conditions, and it may not always present with obvious signs or symptoms, leading to delays in diagnosis.

Q. What is the A-tool, and how does it work?
A. The A-tool is an online screening questionnaire that consists of a brief set of clinical questions. It helps identify people who may have axSpA and guide them to the right care more quickly, without requiring specialized imaging or blood tests.

Q. How effective was the A-tool in detecting axSpA?
A. According to the study, the A-tool increased the probability of detection from 5% to 33%, which is a huge improvement.

Q. What are the benefits of using the A-tool for patients with chronic back pain?
A. The A-tool can help patients identify potential warning signs of axSpA and guide them to seek timely referral to a rheumatologist, potentially leading to early diagnosis and effective treatment.

Q. Who developed the A-tool, and what is their goal?
A. Abhijeet Danve, an associate professor of medicine at Yale School of Medicine, developed the A-tool along with his colleagues. His broader goal is patient empowerment toward early diagnosis and effective treatment.

Q. What are some potential treatments for axSpA?
A. Biologic therapies can improve function and quality of life in patients with axSpA.

Q. Why is it important to recognize axSpA early?
A. Early recognition of axSpA can open the door to effective treatment, including biologic therapies that improve function and quality of life.

Q. How many participants were involved in the study, and what was the outcome?
A. Over 1,200 patients who reported chronic back pain participated in the study, with about one in three (33%) being diagnosed with axSpA.

Q. What is Danve’s vision for the future of the A-tool?
A. Danve hopes to refine the A-tool further by modifying the questionnaire and creating an online calculator that is accessible to anyone, ultimately empowering patients to spot warning signs sooner and bring relief to those living with back pain.